Омепразол-Тева

Quick links

Choose a section

Quick links to important sections

Advertisements

Омепразол-Тева

Advertisements

Overview of Омепразол-Тева

What Type of Medicine is Омепразол-Тева?

Омепразол-Тева is a medicinal preparation whose core identity is defined by its active ingredient, Omeprazole, which functions as a Gastric Acid Suppressant. This drug is classified as a Proton Pump Inhibitor (PPI), a pharmacological class recognized for its role in controlling acid production. Its designation as an antisecretory compound distinguishes it as an agent for managing conditions driven by stomach acid secretion.


Composition and Origin: Is Omeprazole-Teva a Natural or Synthetic Drug?

The active ingredient, Omeprazole, is a synthetic compound belonging to the substituted benzimidazole chemical class. Омепразол-Тева is a single-ingredient product marketed by the manufacturer Teva and is available for oral administration, typically supplied as delayed-release capsules or tablets. This specialized dosage form is utilized because Omeprazole is a light- and acid-sensitive substance, formulated as enteric-coated granules or pellets. This coating protects the drug from being neutralized by stomach acid, ensuring it passes to the small intestine where it can be absorbed and reach its therapeutic target.


What is the Main Purpose of an Acid Suppressant Like Omeprazole?

The primary purpose of Omeprazole is to cause a reduction of gastric acid secretion. This functional benefit is achieved by the drug's targeted action on the H^+,K^+-ATPase enzyme system, which represents the final stage of acid production in the stomach. By lowering acid levels, the medication helps to relieve the discomfort often associated with acid backup. This effect provides a supportive environment for the natural healing of irritated tissues in the upper digestive tract. The control over the intragastric pH is the defining therapeutic characteristic of this medicine, making it a standard choice for suppressing stomach acid.

Regulatory References

  1. Omeprazole: MedlinePlus Drug Information
Advertisements

What side effects are possible with Омепразол-Тева?

Possible Side Effects and Safety Information

Omeprazole-Teva (Omeprazole) is generally well-tolerated, but like all medications, it can cause adverse reactions. These reactions are typically categorized by the frequency of their occurrence, as documented in regulatory filings.


Adverse Reaction Scope

Common Adverse Reactions (incidence ge 2%)

The most frequently reported adverse reactions include gastrointestinal effects such as abdominal pain, nausea, vomiting, diarrhea, and flatulence, as well as headache.

Serious and Clinically Significant Adverse Reactions

Although rare, several serious adverse reactions have been documented, requiring immediate attention. These include:

  • Acute Tubulointerstitial Nephritis (TIN): A kidney disorder that can occur at any point during treatment.
  • Severe Cutaneous Adverse Reactions (SCARs): Including Stevens-Johnson syndrome and toxic epidermal necrolysis.
  • Clostridium difficile-Associated Diarrhea (CDAD): PPI therapy may increase the risk of this infection.
  • Bone Fracture Risk: Long-term and high-dose therapy is associated with an increased risk of osteoporosis-related fractures of the hip, wrist, or spine.
  • Hypomagnesemia and Vitamin B-12 Deficiency: These risks are associated primarily with prolonged daily use (typically ge 1 year).

Safety-Related Restrictions and Limitations

  • Contraindications: Omeprazole is contraindicated in patients with a known hypersensitivity to the drug, substituted benzimidazoles, or any excipients. Concomitant use with nelfinavir is also contraindicated.
  • Symptom Masking: Symptomatic response to omeprazole does not rule out the presence of gastric malignancy; further diagnostic evaluation is necessary if warranted.
  • Drug Interactions: Caution is required with medications metabolized by CYP2C19, such as clopidogrel, due to the potential for reduced efficacy of the co-administered drug.
Advertisements

Overdose and Emergency Response

Overdose and when to seek help

This section details the officially documented manifestations and required emergency actions for Omeprazole-Teva overdose, based solely on authoritative government regulatory labeling, and is provided without interpretation or clinical advice.

Documented Overdose Profile

Element Official Regulatory Statement
Documented Manifestations Symptoms are typically transient and include gastrointestinal effects (nausea, vomiting, diarrhea, abdominal pain) and systemic effects (headache, drowsiness, tachycardia, confusion).
Severity Classification Overdose is generally considered to be of low acute toxicity and is not associated with serious clinical outcome when the medication is taken alone.
Antidote Information No specific antidote is known for Omeprazole overdose.
Supportive Management Treatment should be symptomatic and supportive. Regulatory documents state that measures such as gastric lavage and administration of activated charcoal may be considered if performed early after ingestion.

When Urgent Medical Help Is Required

  • Required Action: Seek emergency medical attention or contact a Poison Control Center right away in the event of any known or suspected overdose, as explicitly mandated by regulatory authorities.
  • Monitoring: The patient's clinical condition dictates the level of observation and monitoring required by healthcare professionals.

The regulatory documents define the overdose profile by its low acute toxicity and transient nature of symptoms. This profile determines the treatment strategy, which focuses on supportive measures in the absence of a specific antidote. Despite the low documented severity, official labeling unequivocally mandates that users seek immediate medical attention for all suspected over-ingestions.

Advertisements

Therapeutic Uses of Омепразол-Тева

Quick Facts: Uses of Омепразол-Тева

  • May assist in the management of gastroesophageal reflux disease (GERD).
  • May promote the healing of duodenal and gastric ulcers.
  • Used in the therapeutic plan for erosive esophagitis.
  • May be utilized to manage pathological hypersecretory conditions, such as Zollinger-Ellison syndrome.

Омепразол-Тева (Omeprazole-Teva) is a prescription medication authorized for the management of various conditions linked to excess stomach acid. The therapeutic goal is to help promote relief and healing for affected tissues.

Key applications include the treatment of duodenal and gastric ulcers. It may be used as part of a combination regimen with antibiotics to address ulcers associated with Helicobacter pylori (H. pylori) infection. Additionally, it may assist in the short-term healing and long-term maintenance of erosive esophagitis, which involves damage to the esophagus caused by acid reflux.

This medication is also applied in the symptomatic treatment of gastroesophageal reflux disease (GERD), addressing the symptoms of heartburn and acid regurgitation. Furthermore, it serves in the extended management of pathological hypersecretory conditions, which are characterized by the stomach producing abnormally large amounts of acid.

Regulatory References

  1. NIH MedlinePlus guidance
Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Omeprazole-Teva

Official regulatory guidelines define specific populations who are prohibited from using Omeprazole-Teva and others who require conditional use. The medication is contraindicated in patients with a known hypersensitivity to omeprazole, substituted benzimidazoles, or any component of the formulation. It must also not be used concomitantly with the antiretrovirals nelfinavir or rilpivirine.

Age Group Eligibility Status
Adults (≥ 17 years) Established/Allowed for all approved uses.
Children Established for certain conditions at ≥ 1 year of age and ≥ 10 kg.
Infants (< 1 year) Use not established; generally not recommended.

Eligibility is limited by organ function; patients with hepatic impairment (liver disease) are eligible but require restricted use and often a reduced maximum dose. For patients with renal impairment (kidney function), no dose adjustment is needed. Use in pregnant women is generally allowed, but use in nursing mothers is not recommended.

Advertisements

What should I know about interactions with other medicines?

The official regulatory profile for Omeprazole-Teva is structured around two primary interaction patterns: its significant effect on intragastric acidity and its influence on liver enzymes.

Contraindicated and Restricted Combinations

Co-administration with the antiretrovirals Nelfinavir and Atazanavir is prohibited or strongly discouraged by regulatory agencies. This restriction is based on Omeprazole causing a substantial reduction in the plasma concentrations of these medicines.

The combination with the antiplatelet drug Clopidogrel is also discouraged because Omeprazole inhibits the CYP2C19 enzyme, which reduces the active metabolite's required concentration. Official studies confirm that separating the administration time of Omeprazole and Clopidogrel does not prevent this interaction.

Altered Drug Exposure

By elevating the intragastric pH, Omeprazole can reduce the absorption and exposure of drugs that require stomach acid for dissolution, such as certain antifungals like Ketoconazole and Itraconazole. Conversely, this pH change may increase the concentration of drugs like Digoxin in the bloodstream. Omeprazole's inhibition of the CYP2C19 enzyme can increase the systemic exposure of co-administered drugs like Diazepam, Phenytoin, and Cilostazol. Furthermore, Omeprazole may elevate or prolong concentrations of Methotrexate and increase levels of Tacrolimus.

Strong enzyme inducers, including Rifampicin and the herbal product St. John's Wort, are documented to reduce Omeprazole exposure and should be avoided.

Procedural Constraints

To avoid interference with diagnostic results, Omeprazole must be temporarily stopped for at least 14 days before certain tests, such as Chromogranin A (CgA) testing. Regulatory notes indicate that the potential for drug interactions is heightened in patients with hepatic impairment due to reduced clearance.

Advertisements

Mechanism of Action

Омепразол-Тева (Omeprazole-Teva) belongs to the class of Proton Pump Inhibitors (PPIs). Its mechanism of action centers on an irreversible interaction with a key enzyme system in the stomach lining, leading to a profound reduction in acid secretion.


Irreversible Enzyme Inhibition

This mechanistic domain involves the drug's direct molecular interaction with its target. Омепразол-Тева is a prodrug that becomes activated in the highly acidic environment of the stomach's parietal cells. Its active form then covalently and irreversibly binds to specific cysteine residues on the H+/K+-ATPase enzyme (the proton pump). This action irreversibly binds to and inhibits the enzyme, preventing the final transport of hydrogen ions in the acid secretion pathway.


Regulation of Gastric Acid Secretion

The inhibition of the proton pump leads to the primary physiological effect. By directly and selectively inhibiting the H+/K+-ATPase, which is responsible for exchanging hydrogen ions (protons) for potassium ions, Омепразол-Тева modifies a key pathway in the digestive system. This results in a pronounced suppression of both basal and stimulated gastric acid production, decreasing the concentration of hydrogen ions in the gastric lumen.

Advertisements

Dosage and Administration Information

How to Use Омепразол-Тева

Омепразол-Тева is administered via the oral route, typically as delayed-release capsules or tablets. In clinical settings where oral intake is not feasible, the medicine may be administered as an intravenous infusion.

Dosing Patterns and Administration Timing

The standard regimen for most acute conditions, such as the healing of duodenal ulcers or erosive esophagitis, involves a once-daily dose of 20 mg or 40 mg. For the maintenance of healing, a lower daily dose, such as 10 mg or 20 mg, may be employed. In therapeutic plans for H. pylori eradication, Omeprazole is typically used at 20 mg twice daily as part of a combination regimen.

For pathological hypersecretory conditions, the initial dose is often 60 mg once daily; however, total daily dosages exceeding 80 mg must be given in divided doses to ensure sustained acid suppression.

Oral delayed-release dosage forms must be taken before eating, preferably in the morning, to optimize the drug's effect. The capsule or tablet must be swallowed whole with a liquid. It is a procedural requirement that the medicine must not be crushed or chewed to preserve the integrity of the enteric coating.

Procedural and Population Rules

If a dose is missed, patients should take it as soon as remembered unless it is within 12 hours of the next scheduled dose, in which case the missed dose should be skipped; a double dose must not be taken. For older adults (>65 years), no dose adjustment is generally needed. Dosing for pediatric patients is determined based on weight, as authorized for children 1 month of age and older for specific conditions.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Омепразол-Тева

The clinical evaluation of Omeprazole-Teva is based on research that examines the drug’s role in conditions related to excess stomach acid. The research base primarily consists of Randomized Controlled Trials (RCTs), where patient groups are studied under carefully managed conditions, supported by systematic reviews and meta-analyses that combine findings from multiple studies. This overview describes the research landscape according to authorized uses and highlights areas where data remains limited.


Evidence for Symptom Management and Healing of Esophageal Tissues

Research has been conducted for conditions characterized by fluctuating or episodic manifestations of acid reflux. Studies utilized RCTs to explore how symptoms change over time and to examine outcomes related to healing of physical damage in the food pipe (esophagus).

For Symptomatic Gastroesophageal Reflux Disease (GERD), studies were conducted to measure patient-reported outcomes describing perceived discomfort. Short-term assessments were the main focus of trials. Research also monitored shifts in intragastric pH (the acidity level of the stomach). Long-term outcomes are not fully established, and evidence remains limited or heterogeneous regarding the sustained management over extended time periods.

Research for Healing and Maintenance of Erosive Esophagitis (EE)

Formal regulatory studies and RCTs were applied in research exploring outcomes related to the healing of Erosive Esophagitis (EE), which is tissue damage caused by acid. Researchers studied outcomes related to inflammatory or irritative states by measuring the actual healing rate of the erosions using endoscopic assessment and measures of relapse or recurrence.


Evidence for Peptic Ulcer Treatment and H. pylori Eradication

Research explored activity related to conditions associated with acute episodes, specifically Peptic Ulcer Disease (PUD). For active ulcers, Phase 3 clinical trials and RCTs examined outcomes related to physical discomfort and ulcer healing. Data were collected related to ulcer healing over typical short-term follow-up durations, ranging from two to eight weeks.

Research for H. pylori Eradication Regimens

The medicine was studied for use as part of combination regimens with antibiotics to address ulcers associated with Helicobacter pylori ( H. pylori) infection. Research examined the success rate of eliminating the bacteria (eradication rate) confirmed by laboratory testing. Findings described an association between successful eradication and measured patterns of ulcer recurrence. It is noted that results apply only to the populations studied, and eradication success may be influenced by local antibiotic resistance patterns.


What is Still Uncertain About the Research Base for Omeprazole

Evidence quality varies across studies, particularly for rare conditions like hypersecretory syndromes, where reliance on smaller, non-randomized studies is common. Long-term effects are not fully established across all indications, and subgroup findings are uncertain in specific populations, such as in some key pediatric studies.

Key Studies & References

  1. Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: a prospective study (Long-term Open-Label/Case Series Evidence)
  2. 25 Years of Proton Pump Inhibitors: A Comprehensive Review (Systematic Review for GERD/Ulcers/ZES)
  3. Omeprazole - StatPearls (Authoritative Clinical Summary/Review for all indications and populations)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Омепразол-Тева (FAQ)

Q: Is Омепразол-Тева the same as regular omeprazole?

A: The active ingredient in Омепразол-Тева is omeprazole. Official documents indicate that omeprazole is the core chemical compound found in both this branded product and generic omeprazole medicines.

Q: What is the difference between Омепразол-Тева and other medicines for stomach acid?

A: Омепразол-Тева is classified as a Proton Pump Inhibitor (PPI), meaning it provides sustained acid reduction by blocking the final step of acid production. Medicines like antacids, in contrast, offer immediate but temporary relief by neutralizing existing acid. Regulatory information confirms that taking omeprazole with antacids is generally safe.

Q: How quickly does Омепразол-Тева start working?

A: Official product information describes the onset of the acid-reducing effect occurring within one hour, with maximum effect generally reached within two hours of administration. However, it may take between one and four days of continuous use before the full, intended acid-suppressing effect is observed.

Q: How long does the effect of Омепразол-Тева usually last?

A: The drug works by irreversibly binding to the proton pump enzyme in the stomach. Official pharmacodynamics data indicate that the duration of acid inhibition resulting from this action can last up to 72 hours (three days).

Q: Is Омепразол-Тева meant for long-term use?

A: Over-the-counter use is generally limited to a 14-day treatment course. For prescription use, regulatory criteria focus on using the lowest effective dose for the shortest duration appropriate for the treated condition. Long-term use (typically one year or longer) is associated with warnings regarding an increased risk of bone fracture, B-12 deficiency, and low magnesium levels.

Q: What is rebound acid production, and is it a concern with Омепразол-Тева?

A: Rebound acid production refers to increased acid secretion after stopping the medicine. Regulatory data reports that when the medicine is stopped, acid secretory activity does not immediately return. Instead, it is described as returning gradually over a period of three to five days.

Q: Does Омепразол-Тева cause tiredness or fatigue?

A: Fatigue is listed as an adverse reaction in some official regulatory documents, sometimes categorized as common or uncommon. Official reports also note a risk of low magnesium levels (hypomagnesemia) with long-term use, and this risk is listed alongside fatigue in some documentation.

Q: Can Омепразол-Тева affect sleep?

A: Official documentation includes insomnia (trouble sleeping) as a reported adverse reaction. Other sleep disturbances have also been noted in postmarketing reports.

Q: Is there a link between taking Омепразол-Тева and changes in mood?

A: Rarely reported side effects include changes in mood or psychological state. Regulatory documents list depression, aggression, agitation, and reversible mental confusion in postmarketing reports.

Q: What is the difference between prescription and over-the-counter Омепразол-Тева?

A: The active ingredient remains the same in both forms. The over-the-counter (OTC) version is intended to treat frequent heartburn (occurring two or more days per week) for a 14-day course. The prescription version is used for conditions that require medical diagnosis and doctor supervision, such as ulcers or erosive esophagitis.

Q: Is there evidence for using Омепразол-Тева to help with difficulty swallowing?

A: The medicine is indicated for conditions like Gastroesophageal Reflux Disease (GERD), which may cause difficulty swallowing. Official warnings note that the regulatory label advises seeking diagnostic evaluation if symptoms like trouble or pain swallowing food occur, as this may be a sign of a serious underlying condition.

Q: Has Омепразол-Тева been studied in different ethnic groups?

A: Official prescribing information notes that certain population groups may exhibit differences in how the drug is metabolized. Dosage adjustment considerations are sometimes noted for patients of Asian heritage due to variation in drug metabolism rates.

Q: Can Омепразол-Тева be taken with antacids?

A: Yes, official guidelines generally confirm it may be safe to take omeprazole with antacids for immediate symptom relief. However, some regulatory sources suggest spacing the doses by several hours to ensure the omeprazole's full acid-blocking effect is maintained.

Q: Are there specific food restrictions while using Омепразол-Тева?

A: While regulatory instructions define when to take the medicine in relation to food, they do not impose specific food restrictions. However, official patient materials often list common heartburn triggers, such as spicy, fatty, or fried foods, as substances that may be avoided as a general lifestyle measure for symptom management.

Q: Can drinking coffee or alcohol affect Омепразол-Тева?

A: Official patient materials often list alcohol and caffeine as substances that may be avoided as a general lifestyle measure to reduce heartburn symptoms. These substances are well-known to trigger or worsen the very symptoms the medication is intended to treat.

Q: Is it safe to drive or operate machinery while taking Омепразол-Тева?

A: Adverse reactions such as dizziness, headache, and visual disturbances have been reported in official documents. Due to these reported effects, caution is advised regarding driving or operating heavy machinery.

Q: Are patients with a history of lupus able to use Омепразол-Тева?

A: Regulatory warnings state that forms of lupus, specifically Cutaneous and Systemic Lupus Erythematosus, have been reported in patients taking Proton Pump Inhibitors (PPIs). This may be a new onset or an exacerbation of an existing condition.

Q: Does Омепразол-Тева interact with supplements like iron or magnesium?

A: Official documents advise that omeprazole can interfere with the absorption of certain supplements that require stomach acid, such as iron salts. Additionally, long-term use is associated with a risk of Hypomagnesemia (low magnesium levels) in the body.

Q: What happens to the drug after it is absorbed by the body?

A: According to official pharmacokinetics data, omeprazole is extensively processed in the liver by the CYP450 enzyme system. This system involves key enzymes such as CYP2C19 and CYP3A4, which are responsible for metabolizing the drug.

Q: Can Омепразол-Тева be taken for short bursts of stomach discomfort?

A: Over-the-counter omeprazole is explicitly described as not intended for immediate relief of occasional heartburn symptoms. Regulatory instructions indicate the drug is to be used as a full 14-day course to treat frequent heartburn.

Q: Is the term 'proton pump inhibitor' the same as Омепразол-Тева?

A: Омепразол-Тева is a medicine that belongs to a specific class of compounds known as gastric acid-pump inhibitors. This pharmacological class is commonly referred to by the term Proton Pump Inhibitor (PPI) and describes the drug's mechanism of action.

Q: What are the criteria for stopping Омепразол-Тева according to official guidelines?

A: Official guidance focuses on the use of the medicine at the lowest effective dose for the shortest duration necessary. The over-the-counter label specifically advises stopping use if symptoms continue or worsen after the recommended course, or if more than one course is required within a four-month period.

Advertisements

How should Омепразол-Тева be stored and disposed of?

How to Store and Dispose of Omeprazole Teva

The storage and disposal requirements for Omeprazole Teva are defined by regulatory authorities to ensure product stability and safety.

Official Storage Conditions

Omeprazole Teva must be stored below 25 C and protected from moisture. The medicine must be kept in the original container and the container must be kept tightly closed to maintain the stability of the active ingredient.

Safety and Disposal Rules

All forms of this medication must be stored out of the sight and reach of children as a mandatory safety requirement.

While the regulatory label states no special precautions for disposal of the unused product are required, standard public health guidance directs that medicines should not be disposed of via wastewater or household waste. Expired or unused Omeprazole Teva should be returned to a pharmacy or designated collection site for safe, environmental disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Омепразол-Тева found in:

A-Z Index: